Glaukos Corp
Chiusa
SettoreSettore sanitario
134.51 3.14
Panoramica
Variazione del prezzo dell'azione
24h
Minimo
131.44
Massimo
135.19
Entrata | 114M -20M |
|---|---|
Vendite | 7.5M 151M |
EPS | -0.18 |
Margine di Profitto | -13.139 |
Dipendenti | 1,094 |
EBITDA | 124M -5.3M |
Raccomandazioni | Fortemente da comprare |
|---|---|
Previsioni per 12 mesi | +17.59% upside |
Utili prossimi | 29 lug 2026 |
|---|
Capitalizzazione di Mercato | 719M 7.9B |
|---|---|
Apertura precedente | 131.37 |
Chiusura precedente | 134.51 |
Notizie sul Sentiment di mercato
By Acuity
50%
50%
143 / 342 Classifica in Healthcare
Glaukos Corp Grafico
Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.
Chi Siamo Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.